Abbott Laboratories  

(Public, NYSE:ABT)   Watch this stock  
Find more results for ABT
42.58
-0.22 (-0.51%)
Real-time:   2:58PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 42.51 - 42.88
52 week 32.70 - 43.27
Open 42.73
Vol / Avg. 1.69M/4.62M
Mkt cap 64.25B
P/E 30.59
Div/yield 0.22/2.07
EPS 1.39
Shares 1.50B
Beta 0.40
Inst. own 69%
Oct 14, 2014
Q3 2014 Abbott Laboratories Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 16, 2014
Q2 2014 Abbott Earnings Release
Jul 16, 2014
Q2 2014 Abbott Laboratories Earnings Call - Webcast
Jul 14, 2014
Abbott Laboratories M&A Call - Mylan Inc Acquisition of Generics Pharmaceuticals Business - Webcast
Jul 14, 2014
Mylan Inc To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction M&A Call
Jun 11, 2014
Abbott Laboratories at William Blair & Company LLC Growth Stock Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 8.29% 10.91%
Operating margin 13.71% 12.03%
EBITD margin - 20.49%
Return on average assets 4.44% 4.33%
Return on average equity 7.85% 9.18%
Employees 69,000 -
CDP Score - 84 B

Address

C/O TAX DEPT D367 & AP6D 100 Abbott Park Road
ABBOTT PARK, IL 60064-3500
United States - Map
+1-847-9376100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products. Abbott operates in four business segments: diagnostics, medical devices, nutritionals and generic pharmaceuticals. Geographically, 30% of its revenue is generated in the United States; 30% in Western Europe, Canada, Japan and Australia, and 40% in the economies, including India, China, Russia and Brazil. In January 2013, the Company completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. In August 2013, Abbott Laboratories completed its acquisition of OptiMedica Corporation. In August 2013, Abbott Laboratories completed its acquisition of IDEV Technologies.

Officers and directors

Miles D. White Chairman of the Board, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Thomas C. Freyman Chief Financial Officer, Executive Vice President - Finance
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Hubert L. Allen Executive Vice President, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
Stephen R. Fussell Executive Vice President - Human Resources
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard W. Ashley Executive Vice President - Corporate Development
Age: 70
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Brian J. Blaser Executive Vice President - Diagnostics Products
Age: 49
Bio & Compensation  - Reuters
John M. Capek Ph.D. Executive Vice President - Medical Devices
Age: 52
Bio & Compensation  - Reuters
Michael J. Warmuth Executive Vice President - Established Pharmaceuticals
Age: 51
Bio & Compensation  - Reuters
Jaime Contreras Senior Vice President - Core Laboratory Diagnostics, Commercial Operations
Age: 57
Bio & Compensation  - Reuters
Georges H. De Vos Senior Vice President - Established Pharmaceuticals, Emerging Markets
Age: 55
Bio & Compensation  - Reuters